Intratumour heterogeneity (ITH) has become an important focus of cancer research in recent
years. ITH describes the cellular variation that enables tumour evolution, including tumour …

Simple Summary Pancreatic ductal adenocarcinoma's (PDAC) dismal prognosis is
associated with its aggressive biological behavior and resistance to chemotherapy …

Mutations in ARID1A rank among the most common molecular aberrations in human cancer.
However, oncogenic consequences of ARID1A mutation in human cells remain poorly …

Pancreatic adenocarcinoma is a malignancy with rising incidence and grim prognosis.
Despite improvements in therapeutics for treating metastatic pancreatic cancer, this disease …

Activating KRAS mutations and functional loss of members of the SWI/SNF complex,
including ARID1A, are found together in the primary liver tumor cholangiocarcinoma (CC) …

ARID1A is a key mammalian SWI/SNF complex subunit that is mutated in 5% to 11% of lung
cancers. Although recent studies have elucidated the mechanism underlying dysregulation …

Cellular dedifferentiation is a key mechanism driving cancer progression. Acquisition of
mesenchymal features has been associated with drug resistance, poor prognosis, and …

Abstract Background & Aims Pancreatic ductal adenocarcinoma (PDAC) arises from several
types of premalignant lesions, including intraductal tubulopapillary neoplasm (ITPN); …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive
malignancy. Recent multi-gene analysis approaches such as next-generation sequencing …

The AT-rich interaction domain 1A (ARID1A, also known as BAF250a) is a chromatin
remodeling gene, which frequently mutates across a broad spectrum of cancers with loss …